Juvenile Arthritis

April 05, 2021

This week, Rheumatology Network sat down with Daniel J. Lovell, MD, MPH, to discuss his study, “Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis.”

April 02, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 2, 2021.

March 29, 2021

Of the 26 autoimmune disease and related conditions studied, 14 (53.8%) had higher prevalence in the juvenile idiopathic arthritis (JIA) group when compared with the general pediatric (GP) population cohort.

October 22, 2020

Children who take oral corticosteroids for autoimmune conditions, such as juvenile arthritis, psoriasis, inflammatory bowel disease or other conditions, like asthma, have an increased risk of diabetes, high blood pressure, and blood clots, say researchers writing in the American Journal of Epidemiology.

October 05, 2020

In juvenile idiopathic arthritis, predictive genomic risk scores may enhance current diagnosis protocols, prioritizing higher-risk patients for follow-up and reducing treatment delays, according to a study published this month in Annals of Rheumatic Diseases.

September 30, 2020

Golimumab (Simponi Aria, Janssen/J&J) has been approved by the U.S. Food and Drug Administration for two pediatric conditions:active pediatric juvenile idiopathic arthritis (JIA) and active pediatric psoriatic arthritis.

September 30, 2020

The U.S. Food and Drug Administration has approved tofacitinib Xeljanz, Pfizer) for the treatment of children and adolescents two years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

July 14, 2020

The U.S. FDA has approved the first treatment for adult-onset Still's disease, a rare form of systemic juvenile idiopathic arthritis associated with high fever, arthritis and rash.

March 03, 2020

Tocilizumab might be a useful adjunctive therapeutic option for children with juvenile idiopathic arthritis-associated uveitis that doesn't respond to TNFi treatment, say researchers recently writing in The Lancet Rheumatology.

November 27, 2019

Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.

November 27, 2019

While the need for orthopedic surgery and the presence of uveitis have diminished over the past 20 years in children with juvenile idiopathic arthritis (JIA), disease activity is present more than 50 percent of the time, say researchers recently writing in Arthritis Research and Therapy.

November 18, 2019

Researchers reporting at the annual meeting of the American College of Rheumatology earlier this month say they have successfully identified a specific biomarker for macrophage activation syndrome, a complication of childhood rheumatic disease most often affecting children with systemic juvenile idiopathic arthritis.

November 14, 2019

In today's slideshow, we highlight the best of the ACR Annual Meeting which wrapped this week in Atlanta. Among the highlights, includes a study that focuses on unusually high death rates in lupus, plus one that suggests new treatments for juvenile idiopathic arthritis are "urgently" needed. Learn more in this slideshow.

November 11, 2019

ACR Annual Meeting:  Monotherapy with abatacept was safe and effective in patients with polyarticular juvenile idiopathic arthritis who couldn’t tolerate or didn’t respond to methotrexate, researchers reported November 11 at the annual meeting of the American College of Rheumatology in Atlanta.

September 13, 2019

From transitioning a pediatric rheumatology patient to adult care to re-evaluating a missed diagnosis, in this slideshow, we highlight some key presentations from the annual Rheumatology Nurses Society meeting held last month. 

September 09, 2019

Better communication between pediatric and adult rheumatologists is especially important as pediatric patients with juvenile idiopathic arthritis transition to adult care.  In this Q&A, we revisit a Rheumatology Nurses Society annual meeting presentation made last month by Cathy Patty-Resk, MSN, RN, CPNP, a pediatric rheumatology nurse practitioner with the Children’s Hospital of Michigan.

August 22, 2019

Children with active rheumatic disease exposed to multiple biological drugs should be monitored for hypersensitivity reactions, particularly during intravenous infusions, say researchers writing in Pediatric Allergy and Immunology this month

June 10, 2019

Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.

June 07, 2019

In April, the FDA approved the etanercept biosimilar etanercept-ykro (Eticovo, Samsung Bioepis) for the same indications as its reference product Enbrel.

May 31, 2019

Early treatment with DMARDs for juvenile idiopathic arthritis polyarthritis is now preferred over beginning patients on NSAID monotherapy, per updated treatment guidelines.